Search research articles
Contact Us
Filters
Showing results (101-110 of 126) with videos related to
Page
of 13
Sort By:
Journal for Immunotherapy of Cancer
|
August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
The New England Journal of Medicine
|
November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutation
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Adriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Journal for Immunotherapy of Cancer
|
April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal, Amy Prawira, Scott Antonia, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
James Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 126) with videos related to
Sort By:
Page
of 13
Journal for Immunotherapy of Cancer
|
August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
The New England Journal of Medicine
|
November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutation
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Adriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Journal for Immunotherapy of Cancer
|
April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal, Amy Prawira, Scott Antonia, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
James Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Page
of 13